Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)

• Status: Withdrawn
• Trial end date: 2020-07-15
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abderrahmane Mami Hospital
• Collaborators: Dacima Consulting; Eshmoun Clinical Research Centre
• Treatments: Azithromycin; Hydroxychloroquine

Criteria

Inclusion Criteria:

• confirmed COVID19 (+)

• Qt<500ms

• no severity criteria

• pauci-symptomatique patients

• signed consent form

Exclusion Criteria:

• no confirmed patient COVID19

• severity criteria

• known allegies to macrolides and HCQ

• Treated with HCQ within 1 month prior to inclusion

• hepatitis insufficiency

• Renal insufficiency

• treatment no indicated with azithro and HCQ

• hypovolemia

• complete brach block

• retinopathia

• psoriasis

• pregnancy or breastfeeding